Brightgene Bio-medical Technology Co., Ltd.

This early-stage study tested a new injectable medication called BGM0504 in adults who are overweight or obese but do not have diabetes. The main goal was to check how safe the drug is, how the body processes it, and if it affects body weight. Thirty participants received either …

This study aimed to understand how a potential new drug for type 2 diabetes and weight management (BGM0504) is processed by the body in people with impaired kidney function compared to healthy people. It was a small, early-stage (Phase 1) trial that measured drug levels in the bl…

This study aimed to understand how a new injection called BGM0504 might affect how quickly the stomach empties and how the body processes two common medications, metformin and warfarin. It involved 28 overweight or obese participants. The main goal was to gather safety and intera…